* If you want to update the article please login/register
With reduced ejection fraction, the aim of this review was to investigate the effects of sacubitril/valsartan on right ventricular function in patients with pulmonary hypertension due to heart failure. Both treatment groups improved the following parameters after six months of hospitalization, left atrium, left ventricle, the left ventricular ejection system, and RV systolic function. Sacubitril/valsartan seems to have more pronounced results in patients with HFrEF-induced PH to enhance RV function, as well as a decrease in pulmonary pressure.
Source link: https://doi.org/10.1002/pul2.12034
This paper was designed to investigate the role of felodipine and enalapril in the treatment of patients with essential hypertension and coronary artery disease. The control group received felodipine alone, and the study group was treated with a mixture of felodipine and enalapril. The post-treatment systolic blood pressure in the study group was 119. 77 mm Hg and diastolic blood pressure, both of which were significantly lower than those in the control group, with statistically significant differences indicating statistically significant differences. The study group's post-treatment peripheral blood Salusin-u03b2. 53 mg/L, and Apelin was 1. 93 u00b10. 58 mg/L, with statistically significant differences compared to the control group. After administration, the PON1 gene expression in the study group was higher than that in the control group.
Source link: https://doi.org/10.14715/cmb/2021.67.6.24
In five European countries, using a novel age-appropriate formulation of enalapril orodispersible minitablets, phase II/III open-label, multicenter pharmacokinetic bridging studies were conducted in pediatric patients with heart failure due to dilated cardiomyopathy and congenital heart disease. Enalapril and its active metabolite enalaprilat had the primary aim of determining the PK parameters of the drug enalapril and its active metabolite enalaprilat. The primary PK endpoint review included 102 patients and 89 patients. Enalapril and its active metabolite enalaprilat were listed in the form of potential PK modifying factors, and etiology and age could be considered as potential PK modifying factors.
Source link: https://doi.org/10.3390/pharmaceutics14061163
We hypothesized that diabetes stimulates the intestinal renin-angiotensin system, contributing to intestinal pathology. The twelve-week-old male rats were divided into three groups: controls, diabetic, and diabetic treated with enalapril were divided into three groups: controls, diabetic, and diabetic. To determine morphology and RAS expression in the jejunum and colon, histological examination and RT-qPCR were carried out. The stools, portal, and systemic blood samples of SCFA and TMAO were analyzed, as well as their systemic blood. The diabetic rats' blood pressures increased, colonic and intestinal mucosa, increased plasma SCFA, and marginally elevated plasma TMAO in comparison to the controls. In the jejunum, Diabetic rats had a lower expression of Mas receptor and angiotensinogen, but diabetic rats had a higher number of Mas receptor and angiotensinogen, whereas, in the colon, the expression of MasR and renin was higher in diabetic rats. In the colon, Enalapril-treated rats had a lower incidence of MasR in the colon. Future studies will need to investigate the clinical significance of intestinal pathology in diabetes.
Source link: https://doi.org/10.3390/ijms23116060
Previous studies show that variant rs71647871 in the CES1 gene promotes enalapril's pharmacokinetics on liver samples as well as healthy volunteers. 286 Caucasian patients with arterial hypertension who received enalapril were included in this study. Before subsequent intake of the drug and 4 h after it was applied with high-performance liquid chromatography and mass spectrometric analysis, the amounts of enalapril and enalaprilat were determined. Mean peak and trough enalaprilat concentrations were significantly lower in CES1 rs2244613 heterozygotes and in CC homozygotes versuss. the AA genotype.
Source link: https://doi.org/10.3390/jpm12040580
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions